Breaking Finance News

RHOEN-KLINIKUM (ETR:RHK) stock price target bumped up to 31.00EUR, reported earlier today by Commerzbank AG

Only yesterday RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even at 27.46EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. With the last stock close up 0.00% from the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the date range. Trading volume was held steady, with 0 shares of RHK changing hands on par with the typical 0 shares..

Stating a possible upside of 0.13%, Commerzbank AG raised the target price of RHOEN-KLINIKUM (ETR:RHK) to 31EUR

Previously on Monday September 19 2016, Commerzbank AG released a statement on RHOEN-KLINIKUM(ETR:RHK) upped the target price from 0.00EUR to 31.00EUR. At the time, this suggested an upside of 0.13%.

Recent Performance Graph:


RHOEN-KLINIKUM has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a total market value of 0.0 EUR.


Rhoen Klinikum AG is a Germany-based provider of health care services. It is primarily engaged in building, acquiring and operating privately owned hospitals. The Company’s portfolio comprises basic and standard care, intermediate care, maximum care, specialist care, medical care centers (MVZ) at hospitals, portal clinics, university hospitals and academic teaching hospitals. These hospitals offer treatment in several specialist fields, including psychiatry, anesthesiology, dermatology, ophthalmology, various types of surgery, women’s medicine and obstetrics, geriatrics, neurology, rehabilitation, urology and internal medicine, among others. The Company operated a number of hospitals and medical care centers. In addition to the hospitals in Bad Berka, Frankfurt, Hildesheim, Karlsruhe, Munich, Pforzheim and Wiesbaden, among others, it has MVZ companies located in Germany, and as well as two research and education companies and service companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *